KKM-191-D by Genuone Science for Type 2 Diabetes: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KKM-191-D overview

KKM-191-D is under development for the treatment of type 2 diabetes. The drug candidate is an incrementally modified drug.

For a complete picture of KKM-191-D’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Transforming preventative care in the NHS – Pharmaceutical Technology

The latest webinar from EMIS, a leading healthcare technology provider, showcased its Pathway platform—a robust tool designed to improve the delivery of preventative care interventions

December 12, 2024

Finding That APOE4 Is Toxic in Alzheimer’s Can Help Guide Targeted Therapies

A working group of senior investigators, convened by the Alzheimer’s Disease Sequencing Project (ADSP), has reached a consensus that the APOE4 gene, long debated in

August 31, 2024

Air pollution linked to head and neck cancer risk

Increased PM2.5 levels are linked to higher head and neck cancer risk, particularly in disadvantaged communities, highlighting urgent public health measures.

November 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.